Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02189161 · ClinicalTrials.gov registry record · NA
A Safety and Tolerability of Circumferential Anal Canal Radiofrequency Ablation For Anal Intraepithelial Neoplasia
A NA study, sponsored by Medtronic - MITG.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT02189161 is a NA study that has completed, run by Medtronic - MITG. The registered enrollment target is 10 participants.
The verdict
NCT02189161, a NA study, has completed, sponsored by Medtronic - MITG.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
Assess the safety, feasibility, and patient tolerability of circumferential radiofrequency ablation (RFA) to the anal canal for patients with anal intraepithelial neoplasia (AIN). Patients will have AIN with high grade squamous intraepithelial lesions (HSIL) and the RFA will be applied using the Barrx™ Ablation System.
Interventions
- DEVICE Radiofrequency Ablation (Barrx™)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2014-07 |
| Est. Completion | 2015-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02189161
The ClinicalTrials.gov registry entry for NCT02189161 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic - MITG, which has 119 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Radiofrequency Ablation (Barrx™) is the first listed.
NCT02189161 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02189161 about?
NCT02189161 is a clinical study titled "A Safety and Tolerability of Circumferential Anal Canal Radiofrequency Ablation For Anal Intraepithelial Neoplasia". Assess the safety, feasibility, and patient tolerability of circumferential radiofrequency ablation (RFA) to the anal canal for patients with anal intraepithelial neoplasia (AIN). Patients will have AIN with high grade squamous intraepithelial lesions (HSIL) and the RFA will be applied using the Bar...
What is the current status of trial NCT02189161?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2014-07. Estimated completion is 2015-08.
What interventions are being tested in trial NCT02189161?
The interventions under investigation include: Radiofrequency Ablation (Barrx™) (DEVICE).
Who is sponsoring clinical trial NCT02189161?
This trial is sponsored by Medtronic - MITG, which has 119 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.